Spero Therapeutics reports Q3 loss and revenue miss, shares declined 10.9% this year.

From Nasdaq: 2024-11-14 17:35:02

Spero Therapeutics, Inc. (SPRO) reported a quarterly loss of $0.32 per share, missing the Zacks Consensus Estimate of a loss of $0.27. This represents an earnings surprise of -18.52%. Revenues for the quarter were $13.47 million, falling short of expectations by 41.44%.

The company has surpassed consensus EPS estimates two out of the last four quarters. Spero Therapeutics shares have declined by 10.9% this year, compared to the S&P 500’s gain of 25.5%. What’s next for the stock remains uncertain.

Phreesia (PHR) is expected to report a quarterly loss of $0.29 per share, with revenues of $106 million, up 15.7% from the year-ago quarter. The consensus EPS estimate has remained unchanged over the last 30 days. Results are expected to be released on December 9.



Read more at Nasdaq: Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates